Abstract
Selecting outcomes for clinical trials requires a wide range of considerations relating to clinical interpretation, ethics relating to therapy effectiveness and safety, and statistical optimality of measures. Appropriate outcome choice plays a key role in determining the usefulness and/or success of a study and can affect whether a proposed study is view favorably by funding and regulatory agencies. Many regulatory and funding agencies provide guidance on the types of outcomes that are appropriate or acceptable in various contexts, and it is important to understand regulatory guidelines, definitions, and expectations when choosing clinical outcomes. This chapter provides an overview of the clinical, practical, and statistical considerations in choosing outcomes, with a focus on the intersection between the considerations themselves and the standards and definitions provided by regulatory and funding agencies. Section “Introduction, Definitions, and General Considerations” introduces basic definitions and broad considerations in clinical trials outcomes. Section “Types of Outcome Measures” discusses clinical distinctions between outcomes, mathematical descriptions of outcomes, and safety considerations. Section “Choosing Outcome Measures” discusses both statistical and practical considerations in outcome choice, introduces approaches for evaluating the quality of selected outcomes, and makes distinctions in reporting outcomes. Section “Multiple Outcomes” examines the intricacies involved in using multiple outcomes, specifically multiple outcomes consisting of different, but possibly related, measures, and longitudinal studies that measure the same outcome for multiple times.
This is a preview of subscription content, log in via an institution to check access.
References
Barker-Collo SL (2005) Within session practice effects on the PASAT in clients with multiple sclerosis. Arch Clin Neuropsychol 20:145–152. https://doi.org/10.1016/j.acn.2004.03.007
Bartko JJ (1966) The intraclass correlation coefficient as a measure of reliability. Psychol Rep 19:3–11
Bauer DJ, Sterba SK (2011) Fitting multilevel models with ordinal outcomes: performance of alternative specifications and methods of estimation. Psychol Methods 16(4):373–390. https://doi.org/10.1037/a0025813
Benjamini Y, Cohen R (2017) Weighted false discovery rate controlling procedures for clinical trials. Biostatistics 18(1):91–104. https://doi.org/10.1093/biostatistics/kxw030
FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. Silver Spring (MD): Food and Drug Administration (US); 2016-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK326791/ Co-published by National Institutes of Health (US), Bethesda (MD).
Carpenter JR, Kenward MG (2007) Missing data in randomised controlled trials – a practical guide. National Institute for Health Research, Birmingham
Chen J, Luo J, Liu K, Mehrotra DV (2011) On power and sample size computation for multiple testing procedures. Comput Stat Data Anal 55:110–122
Cohen JA, Cutter GR, Jill FS, Goodman AD, Heidenreich FR, Jak AJ, … Whitaker JN (2001) Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 58: 961–967
Cohen JA, Reingold SC, Polman CH, Wolinsky JS (2012) Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurol 11:467–476
Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau KS, … Reingold S (1999) Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 122(5): 871–882. https://doi.org/10.1093/brain/122.5.871
Edwards LJ, Simpson SL (2014) An analysis of 24-hour ambulatory blood pressure monitoring data using orthonormal polynomials in the linear mixed model. Blood Press Monit 19(3):153–163. https://doi.org/10.1097/MBP.0000000000000039
FDA (2009) Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. U.S. Department of Health and Human Services Food and Drug Administration. Retrieved from https://www.fda.gov/downloads/drugs/guidances/ucm193282.pdf
FDA (2017) Multiple endpoints in clinical trials: guidance for industry. U.S. Department of Health and Human Services Food and Drug Administration. Retrieved from https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm536750.pdf
Haime M (2016) Somahlution announces study results showing DuraGraft® vascular graft treatment improves long-term outcomes in coronary artery bypass grafting surgery. European Association for cardio-thoracic surgery annual meeting. Barcelona. Retrieved from https://www.somahlution.com/vascular-graft-treatment/
Hedeker D (2015) Methods for multilevel ordinal data in prevention research. Prev Sci 16(7):997–1006. https://doi.org/10.1007/s11121-014-0495-x
Hedeker D, Gibbons RD (2006) Longitudinal data analysis. Wiley, Hoboken
Huque MF, Dmitrienko A, D’Agostino R (2013) Multiplicity issues in clinical trials with multiple objectives. Stat Biopharmaceut Res 5(4):321–337. https://doi.org/10.1080/19466315.2013.807749
Kennedy RE, Cutter GR, Wang G, Schneider LS (2015) Using baseline cognitive severity for enriching Alzheimer’s disease clinical trials: how does mini-mental state examination predict rate of change? Alzheimer’s Dementia: Transl Res Clin Interven 1:46–52. https://doi.org/10.1016/j.trci.2015.03.001
Mallinckrodt CH, Sanger TM, Dubé S, DeBrota DJ, Molenberghs G, Carrol RJ, … Tollefson GD (2003) Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol Psychiatry 53:754–760
Motooka Y, Matsui T, Slaton RM, Umetsu R, Fukuda A, Naganuma M, … Nakamura M (2018) Adverse events of smoking cessation treatments (nicotine replacement therapy and non-nicotine prescription medication) and electronic cigarettes in the Food and Drug Administration Adverse Event Reporting System, 2004–2016. SAGE Open Med 6:1–11. https://doi.org/10.1177/2050312118777953
Pocock SJ (1997) Clinical trials with multiple outcomes: a statistical perspective on their design, analysis, and interpretation. Control Clin Trials 18:530–545
Powney M, Williamson P, Kirkham J, Kolamunnage-Dona R (2014) A review of handling missing longitudinal outcome data in clinical trials. Trials 15:237. https://doi.org/10.1186/1745-6215-15-237
Prentice RL (1989) Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8(4):431–440. https://doi.org/10.1002/sim.4780080407
Shrout PE, Fleiss JL (1979) Intraclass correlations: uses in assessing rater reliability. Psychol Bull 86(2):420–428
Simon R, Maitournam A (2004) Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 10:6759–6763. https://doi.org/10.1158/1078-0432.CCR-04-0496
Sormani MP, Bonzano L, Luca R, Cutter GR, Mancardi GL, Bruzzi P (2009) Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol 65:268–275. https://doi.org/10.1002/ana.21606
Sormani MP, Bonzano L, Luca R, Mancardi GL, Ucceli A, Bruzzi P (2010) Surrogate endpoints for EDSS worsening in multiple sclerosis. A meta-analytic approach. Neurology 75(4):302–309. https://doi.org/10.1212/WNL.0b013e3181ea15aa
Sozu T, Sugimoto T, Hamasaki T (2011) Sample size determination in superiority clinical trials with multiple co-primary correlated endpoints. J Biopharm Stat 21:650–668. https://doi.org/10.1080/10543406.2011.551329
Sozu T, Sugimoto T, Hamasaki T (2012) Sample size determination in clinical trials with multiple co-primary endpoints including mixed continuous and binary variables. Biom J 54(5):716–729. https://doi.org/10.1002/bimj.201100221
Sullivan EJ (n.d.) Clinical trials endpoints. U.S. Food and Drug Administration. Retrieved November 19, 2018, from https://www.fda.gov/downloads/Training/ClinicalInvestigatorTrainingCourse/UCM337268.pdf
Surrogate Endpoint Resources for Drug and Biologic Development (n.d.) U.S. Food and Drug Administration. Retrieved November 19, 2018, from https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ucm606684.htm
Swartz RJ, Schwartz C, Basch E, Cai L, Fairclough DL, Mendoza TR, Rapkin B (2011) The king’s foot of patient-reported outcomes: current practice and new developments for the measurements of change. Qual Life Res 20:1159–1167. https://doi.org/10.1007/s11136-011-9863-1
Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo H-C, Marx A, … Evoli A (2016) Randomized trial of thymectomy in myasthenia gravis. N Engl J Med 375(6):511–522. https://doi.org/10.1056/NEJMoa1602489
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this entry
Cite this entry
Leach, J.M., Aban, I., Cutter, G.R. (2021). Outcomes in Clinical Trials. In: Piantadosi, S., Meinert, C.L. (eds) Principles and Practice of Clinical Trials. Springer, Cham. https://doi.org/10.1007/978-3-319-52677-5_70-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-52677-5_70-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-52677-5
Online ISBN: 978-3-319-52677-5
eBook Packages: Springer Reference MathematicsReference Module Computer Science and Engineering